Clinical Trial Update: Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a combination of atezolizumab, cobimetinib, and eribulin in chemotherapy-resistant metastatic inflammatory breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Breast Cancer

Drugs mentioned

• Cotellic (cobimetinib)
• Halaven (eribulin)
• Tecentriq (atezolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING